Target Corp
Retail
Target Corp (TGT) Stock News
The latest TGT headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·
TGT vs. COST: Which Stock Should Value Investors Buy Now?
Target (TGT) emerges as the superior value option compared to Costco (COST) based on valuation metrics and earnings outlook. TGT holds a Zacks Rank #2 (Buy) with a forward P/E of 15.32 and Value grade of B, while COST has a Zacks Rank #3 (Hold) with a forward P/E of 39.73 and Value grade of D.
- Zacks Investment Research·
Target Stock Up More Than 30% in 6 Months: Is It Too Late to Buy TGT?
Target's stock has surged 34.4% over six months, significantly outperforming peers and the broader market, driven by improving business trends, stronger consumer engagement, and solid digital performance. The company raised fiscal 2026 net sales guidance to around 5% and adjusted EPS guidance to $9.90-$10.90. Trading at 15.86x forward earnings—below industry average but above its one-year median—Target receives a Zacks Rank #2 (Buy) rating, with analysts suggesting existing investors hold while prospective investors gradually build positions.
- Zacks Investment Research·
TGT or COST: Which Is the Better Value Stock Right Now?
A comparison of Target (TGT) and Costco (COST) in the retail discount stores sector reveals that Target presents a better value opportunity. Target has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 15.72, and a Value grade of B. Costco, with a Zacks Rank of #3 (Hold), has a higher forward P/E of 41.75 and a Value grade of D, making it less attractive for value investors.
- Zacks Investment Research·Neutral
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics shares have gained 15.1% since its last earnings report in early September 2026. While the company beat revenue expectations with $240.3M (up 70.3% YoY) driven by strong Briumvi sales, it missed EPS estimates at $0.05 vs. $0.41 expected. The company raised its 2026 revenue guidance to ~$950M. However, analyst estimates have trended downward since the report, and the stock received a Zacks Rank #3 (Hold) with poor Growth and Momentum scores, suggesting limited upside ahead.